Thursday, October 10, 2013
Kidney injury molecule 1, a protein that helps overcome acute kidney injury, now
has been shown by Harvard Medical School researchers to trigger the onset of chronic kidney
disease.1 Companies modulating the target thus need to scrutinize
the therapeutic window of their molecules.
Humphreys' team plans to use conditional
models to overexpress Kim-1 exclusively in adult mice. He said that this should
more closely emulate what happens in humans after an episode of acute injury
and should help distinguish the beneficial effects of KIM-1 in the acute
setting and its negative effects in the chronic arena.
Boettner, B. SciBX 6(39); doi:10.1038/scibx.2013.1085
Published online Oct. 10, 2013
1. Humphreys, B.D. et
al. J. Clin. Invest.; published online Aug. 27, 2013; doi:10.1172/JCI45361
Contact: Benjamin D. Humphreys, Brigham and Women's Hospital, Boston,
2. Leung, K.C.W. et al.
Nat. Rev. Nephrol. 9, 77-85 (2013)
3. Ichimura, T. et al.
J. Clin. Invest. 118, 1657-1668 (2008)
4. van Timmeren, M.M. et
al. J. Pathol. 212, 209-217 (2007)
AND INSTITUTIONS MENTIONED
Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass.
Brigham and Women's Hospital, Boston, Mass.
Harvard Medical School, Boston, Mass.
Genzyme Corp., Cambridge, Mass.
Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.
(Euronext:SAN; NYSE:SNY), Paris, France
The University of Texas MD Anderson Cancer Center, Houston, Texas
X-Rx Inc., Waltham, Mass.